ArticleGut2025
Precision risk stratification of primary gastric cancer after eradication of
Article in Gut, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between map-like redness and the risk of gastric cancer and high-risk precancerous lesions: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- From histological recovery to residual gastric cancer risk afterFrontiers in medicine · 2026Pooled it
- Article
- Article
- From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026Review
- Association ofTranslational cancer research · 2026Article
- Rethinking gastric carcinogenesis: a multiscale ecological model of risk beyondFrontiers in microbiology · 2026Review
- From Tumor Biology to Clinical Perspectives: Novel Biomarkers and Therapeutic Insights in Gastric Cancer.Oncology research · 2026Review
- The Double-Edged Sword of Genomic DNA Methylation: Orchestrating Gastric Carcinogenesis and Shaping Precision Oncology.Oncology research · 2026Review
- TK1 in gastric cancer: Helicobacter pylori-driven oncogenesis biomarker, utility, and emerging targeted therapies.Frontiers in oncology · 2026Review
- Integrated virulence-resistance profiling ofFrontiers in cellular and infection microbiology · 2026Article
- Stratified management of residual gastric cancer risk afterFrontiers in microbiology · 2026Article
- Gastric Cancer after <italic>Helicobacter pylori</italic> Eradication: Characteristics, Diagnosis, and Management.Digestion · 2025Review
- How chronic inflammation fuels carcinogenesis as an environmental epimutagen.Discover oncology · 2025Review
- Spatial Study of TLR4, TLR5 and TLR9 in Gastric Premalignant Lesions Before and AfterInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrecision cancer risk stratification for gastric cancer is urgently needed for the growing number of healthy people after
objectiveTo confirm the clinical usefulness of a DNA methylation marker for epimutation burden, and to identify a cut-off methylation level for a super-high-risk population.
designHealthy people after
results1624 participants had at least one endoscopic follow-up with a median follow-up of 4.05 years, and a primary gastric cancer developed in 27 participants. The highest quartile of
conclusionA DNA methylation marker can risk-stratify healthy people after TRIAL REGISTRATION NUMBER: UMIN-CTR000016894.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.